MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Overall survival

From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first

Time frame: Up to approximately 5 years

Progression free survival on next-line treatment per International Myeloma Working Group criteria

From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first

Time frame: Up to approximately 5 years

Objective response rate per International Myeloma Working Group criteria

From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy

Time frame: Up to approximately 5 years

Duration of response per International Myeloma Working Group criteria

From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first

Time frame: Up to approximately 5 years

Very good partial response or better response rate per International Myeloma Working Group criteria

From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

Time frame: Up to approximately 5 years

Complete response rate per International Myeloma Working Group criteria

From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

Time frame: Up to approximately 5 years

Duration of complete response per International Myeloma Working Group criteria

From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first

Time frame: Up to approximately 5 years

Time to response per International Myeloma Working Group criteria

From date of randomization to date of confirmed objective response

Time frame: Up to approximately 5 years

Minimal residual disease negativity rate per International Myeloma Working Group criteria

From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

Time frame: Up to approximately 5 years

Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria

From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first

Time frame: Up to approximately 5 years

Duration of minimal residual disease negativity rate per International Myeloma Working Group criteria

From date of minimal residual disease negativity to date of relapse, death, or censoring, whichever occurs first

Time frame: Up to approximately 5 years

Frequency of treatment-emergent adverse events

Time frame: From date of first dose of study intervention up to 90 days after last study intervention administration

Frequency of abnormal laboratory results

Time frame: From date of first dose of study intervention up to 90 days after last study intervention administration

Free elranatamab serum trough concentration [Ctrough]

Time frame: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab

Elranatamab immunogenicity by anti-drug antibodies against elranatamab

Time frame: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab

Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30

Change from baseline scores

Time frame: From date of informed consent up to approximately 35 days after last administration of study intervention

Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20

Change from baseline scores

Time frame: From date of informed consent up to approximately 35 days after last administration of study intervention